RESPONSE AFTER FINAL – EXPEDITED PROCEDURE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 0 7 2000

TECH CENTER 1600/2900

CANT: Johannsson et al

SERIAL NO:

09/050,366

GROUP NO: 1653

FILING DATE:

March 31, 1998≪

EXAMINER: F. Moezie Deare Interior

FOR:

USE OF GROWTH

HORMONE

<u>RESPONSE</u>

Honorable Commissioner of Patents and Trademarks

Box AF

Washington, D.C. 20231

Sir:

This is in response to the Office Action dated January 7, 2000.

Please cancel Claims 19-21, and 25-40 without prejudice to their re-entry at some later date.

Please amend the claims as follows.

(Amended) A method for [preventing or] treating a patient having the Metabolic 22.

Syndrome and being [for] non-insulin dependent [diabetes mellitus] which comprises

administering to [a] said patient [in need thereof] growth hormone or a functional derivative

thereof in an amount effective for [preventing or treating non-insulin dependent diabetes

mellitus.] increasing insulin sensitivity of said patient to thereby increase said insulin sensitivity.

Claim 23, line 1 delete "grown" and insert -- growth--.